Nancy E Kohl
Overview
Explore the profile of Nancy E Kohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Crompton B, Carlton A, Thorner A, Christie A, Du J, Calicchio M, et al.
Cancer Res
. 2013 Mar;
73(9):2873-83.
PMID: 23536552
Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade. Tyrosine kinase inhibition is one tractable...
12.
Pan B, Chan G, Chenard M, Chi A, Davis L, Deshmukh S, et al.
Cancer Res
. 2010 Feb;
70(4):1524-33.
PMID: 20145145
The receptor tyrosine kinase c-Met is an attractive target for therapeutic blockade in cancer. Here, we describe MK-2461, a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro...
13.
Ma Y, Zhao S, Zhu J, Bettano K, Qu X, Marshall C, et al.
Biochim Biophys Acta
. 2009 Sep;
1792(11):1073-9.
PMID: 19715759
Polycythemia vera (PV) is a myeloproliferative disorder involving hematopoietic stem cells. A recurrent somatic missense mutation in JAK2 (JAK2V617F) is thought to play a causal role in PV. Therefore, targeting...
14.
Mathur A, Mo J, Kraus M, OHare E, Sinclair P, Young J, et al.
Biochem Pharmacol
. 2009 May;
78(4):382-9.
PMID: 19413997
Polycythemia vera (PV) is a myeloproliferative disorder characterized by increased red cell mass and splenomegaly in the absence of secondary causes [Tefferi A., Spivak J.L., Polycythemia vera: scientific advances and...
15.
Rao S, ONeil J, Liberator C, Hardwick J, Dai X, Zhang T, et al.
Cancer Res
. 2009 Mar;
69(7):3060-8.
PMID: 19318552
NOTCH signaling is deregulated in the majority of T-cell acute lymphoblastic leukemias (T-ALL) as a result of activating mutations in NOTCH1. Gamma secretase inhibitors (GSI) block proteolytic activation of NOTCH...
16.
Zhan Y, Ginanni N, Tota M, Wu M, Bays N, Richon V, et al.
Clin Cancer Res
. 2008 Sep;
14(18):5735-42.
PMID: 18794082
Purpose: For many tumor cells, de novo lipogenesis is a requirement for growth and survival. A considerable body of work suggests that inhibition of this pathway may be a powerful...
17.
Cox C, Coleman P, Breslin M, Whitman D, Garbaccio R, Fraley M, et al.
J Med Chem
. 2008 Jun;
51(14):4239-52.
PMID: 18578472
Inhibition of kinesin spindle protein (KSP) is a novel mechanism for treatment of cancer with the potential to overcome limitations associated with currently employed cytotoxic agents. Herein, we describe a...
18.
Wu Z, Robinson R, Fu S, Barnett S, Defeo-Jones D, Jones R, et al.
Bioorg Med Chem Lett
. 2008 Feb;
18(6):2211-4.
PMID: 18296048
This paper describes the rapid assembly of four different classes of potent Akt inhibitors from a common intermediate. Among them, a pyridopyrimidine series displayed the best intrinsic and cell potency...
19.
Garbaccio R, Tasber E, Neilson L, Coleman P, Fraley M, Olson C, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(20):5671-6.
PMID: 17804233
Observations from two structurally related series of KSP inhibitors led to the proposal and discovery of dihydropyrazolobenzoxazines that possess ideal properties for cancer drug development. The synthesis and characterization of...
20.
Roecker A, Coleman P, Mercer S, Schreier J, Buser C, Walsh E, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(20):5677-82.
PMID: 17766111
Inspired by previous efforts in the pyrazolobenzoxazine class of KSP inhibitors, the design and synthesis of 1,4-diaryl-4,5-dihydropyrazole inhibitors of KSP are described. Crystallographic evidence of binding mode and in vivo...